肢端肥大症中的钙与骨转换标志物:一项前瞻性对照研究
在一项三级转诊中心的前瞻性对照研究中,22例肢端肥大症患者与22例无功能垂体腺瘤对照相比,基线PTH更低、磷更高,骨转换标志物升高且P1NP与CTX强相关。治疗后血钙、磷和CTX下降而PTH升高,25羟维生素D、P1NP及RANK-L/OPG比值无显著变化。
要点
- 肢端肥大症患者基线PTH低于对照、磷高于对照,血尿钙及维生素D水平与对照相似。
- 肢端肥大症患者骨转换标志物高于对照,P1NP与CTX强相关(r²=0.82,P<0.05)。
- 治疗后血钙、磷和CTX下降而PTH升高,P1NP及RANK-L/OPG比值无显著变化。
核心结论
- 肢端肥大症患者表现出不依赖PTH的钙磷改变以及增强的骨形成与骨吸收偶联。
- 治疗6个月内骨吸收下降,而RANK-L/OPG变化不一致。
研究设计与样本
- 前瞻性对照研究,在三级转诊中心纳入22例接受手术或药物治疗的肢端肥大症患者和22例接受手术的无功能垂体腺瘤对照。
- 在基线和治疗后3至6个月检测血尿钙、磷、PTH、25羟维生素D、1,25二羟维生素D、骨转换标志物(CTX、P1NP)及细胞因子(RANK-L、OPG)。
主要发现
- 基线时肢端肥大症组PTH低于对照组(36.3 ± 13.9 pg/mL vs 56.0 ± 19.9 pg/mL),磷高于对照组(4.34 ± 0.71 mg/dL vs 3.55 ± 0.50 mg/dL)(P < 0.01)。
- 两组血钙、尿钙及25羟维生素D、1,25二羟维生素D水平相似。
- 肢端肥大症组骨转换标志物高于对照组,P1NP与CTX强相关(r² = 0.82,P < 0.05)。
- CTX取决于年龄和疾病分组,而与性别或性腺状态无关。
- 肢端肥大症治疗后,血钙(9.52 ± 0.43 mg/dL降至9.26 ± 0.28 mg/dL)、磷(4.34 ± 0.71 mg/dL降至3.90 ± 0.80 mg/dL)和CTX(0.91 ± 0.75 ng/mL降至0.63 ± 0.68 ng/mL)下降,而PTH升高(36.3 ± 13.9 pg/mL升至48.9 ± 16.7 pg/mL)(P < 0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Acromegaly has been associated with calcium-phosphate and bone turnover alterations. Controlled studies of these interactions are sparse. OBJECTIVE: To evaluate calcium and bone metabolism in active and treated acromegaly. DESIGN/SETTING/PATIENTS: We conducted a controlled, prospective study at a tertiary referral center. We studied 22 patients with acromegaly referred for surgical or medical therapy (ACM) and 22 with nonfunctioning pituitary adenomas referred for surgery (control). MAIN OUTCOME MEASURES: Calcium (serum and urine), phosphorus, parathyroid hormone (PTH), 25-hydroxy- and 1,25-dihydroxy-vitamin D, bone turnover markers [serum C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP)], and cytokines [receptor activator of nuclear factor κB ligand (RANK-L) and osteoprotegerin (OPG)] at baseline and 3 to 6 months after treatment. RESULTS: At baseline, the ACM group had lower PTH levels than controls (36.3 ± 13.9 pg/mL vs 56.0 ± 19.9 pg/mL) and higher phosphorus (4.34 ± 0.71 mg/dL vs 3.55 ± 0.50 mg/dL) (P < 0.01). Groups had similar levels of serum and urine calcium and 25-hydroxy- and 1,25-dihydroxy-vitamin D. The ACM group had higher bone turnover markers than control; P1NP and CTX were strongly correlated (r2 = 0.82, P < 0.05). CTX was dependent on age and disease group but not on sex or gonadal status. After treatment of acromegaly, serum calcium (9.52 ± 0.43 mg/dL to 9.26 ± 0.28 mg/dL), phosphorus (4.34 ± 0.71 mg/dL to 3.90 ± 0.80 mg/dL), and CTX (0.91 ± 0.75 ng/mL to 0.63 ± 0.68 ng/mL) decreased, while PTH increased (36.3 ± 13.9 pg/mL to 48.9 ± 16.7 pg/mL) (P < 0.01). 25-hydroxy-vitamin D, P1NP, and RANK-L/OPG ratio did not change significantly. CONCLUSION: Acromegaly patients exhibited PTH-independent calcium-phosphate alterations and enhanced coupled bone formation and resorption. Within 6 months of treatment, bone resorption decreased, whereas RANK-L/OPG changes were inconsistent.
引用
- Constantin T, Tangpricha V, Shah R, et al. Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study. J Clin Endocrinol Metab. 2017. PMID: 28407138. doi:10.1210/jc.2016-3693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。